ArticleFrontiers in immunology2026
Integrative multi-omics reveals the POSTN
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The progression of prostate cancer to lethal castration-resistant (CRPC) and metastatic (mCRPC) stages is driven by a profoundly remodeled tumor microenvironment (TME). However, the identity of key stromal cell populations, their developmental dynamics, and their precise crosstalk with immune cells remain incompletely understood, limiting our ability to target the TME therapeutically. Methods: We integrated single-cell RNA sequencing (scRNA-seq) data from 222,529 cells across 10 studies, encompassing normal prostate, primary tumors, CRPC, and mCRPC. Fibroblast heterogeneity was resolved using unsupervised clustering, trajectory inference (Monocle2), and regulon analysis (pySCENIC). Intercellular communication was deciphered using CellChat. Spatial transcriptomic data were integrated via CellTrek and SpaGene for validation. Clinical associations were evaluated in multiple bulk transcriptomic cohorts (e.g., TCGA-PRAD, IMvigor210) and extended to a pan-cancer atlas of 11 tumor types. Results: We identified a distinct POSTN Conclusions: Our integrated single-cell atlas defines a critical POSTN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.